ringao- between a rock and a hard place
Sprix is running out, needs the new formulation.
Arymo ER is growing, but low Rx and the biggest Q here is: When will they start to make money on Arymo ER? As of today, they made none.
Only w/ Arymo ER making money there would be hope, why could they only collect like $200k in 1Q18?
To overcome the MCAP listing death trap, they would need to swap more debt to equity for cheap - but even the debt (bonds) is traded at BK levels for a while now.
I would love to see a reversal play here, but company is as visible and active as ever: nothing.
Reminder that equity is negative, so there is no value at all for common here until they show a future.
Yes, one way out would be assets sale as described in my earlier post and company stated for at least 2-3 quarters they are willing to do so. That would be the lottery ticket (o8>
But at this point, the SP is not cheap enough - too expensive to lose almost 50c per share on a possible BK for a $1 rebound.
IMHO
News 
Market Data 
Discover 
